Tenax Therapeutics (TENX) Non-Current Deferred Tax Liability (2015 - 2021)

Tenax Therapeutics (TENX) reported Non-Current Deferred Tax Liability of $211590.0 for Q3 2021, down 11.48% sequentially from $239039.0 in Q2 2021.

Tenax Therapeutics (TENX) Non-Current Deferred Tax Liability (2015 - 2021) Analysis & Trends

Tenax Therapeutics (TENX) has 4 years of Non-Current Deferred Tax Liability data on file, last reported at $211590.0 in Q3 2021.

For the quarter ending Q3 2021, Non-Current Deferred Tax Liability changed N/A year-over-year to $211590.0; the trailing twelve-month figure through Sep 2021 stood at $211590.0 (changed N/A YoY), and the FY2020 full-year result was $347.0, changed N/A from the prior year.
Non-Current Deferred Tax Liability fell to $211590.0 in Q3 2021, from $239039.0 in the prior quarter.
In the past five years, Non-Current Deferred Tax Liability ranged from a high of $239039.0 in Q2 2021 to a low of $347.0 in Q4 2020.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn
4	NuCana	279.75 Bn	279.75 Bn	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn
7	Belite Bio	62.51 Bn	62.51 Bn	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn
9	Revolution Medicines	37.78 Bn	37.78 Bn	-
10	Tenax Therapeutics	67,856.40	67,856.40	-

Download Data